ReviewRadiology and oncology2018
State of the art in magnetic resonance imaging of hepatocellular carcinoma.
Review in Radiology and oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Can MRI features predict clinically relevant hepatocellular carcinoma genetic subtypes?Abdominal radiology (New York) · 2023Article
- Bi-specific T1 positive-contrast-enhanced magnetic resonance imaging molecular probe for hepatocellular carcinoma in an orthotopic mouse model.World journal of gastrointestinal oncology · 2022Article
- The Value of CT Perfusion Parameters and Apparent Diffusion Coefficient Value of Magnetic Resonance Diffusion Weighted Imaging in Diagnosis of Hepatocellular Carcinoma.Computational and mathematical methods in medicine · 2022Article
- Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies.Oncology and therapy · 2021Review
- Radiogenomics of gastroenterological cancer: The dawn of personalized medicine with artificial intelligence-based image analysis.Annals of gastroenterological surgery · 2021Review
- Value of gadoxetic acid-enhanced MRI for microvascular invasion of small hepatocellular carcinoma: a retrospective study.BMC medical imaging · 2021Article
- [Magnetic resonance elastography of the liver : Worth knowing for clinical routine].Der Radiologe · 2020Review
- PLZF and PLZF-MAPK10 can predict the prognosis of postoperative patients with hepatocellular carcinoma.International journal of clinical and experimental pathology · 2020Article
- Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?Journal of hepatocellular carcinoma · 2020Article
- Hepatocellular carcinoma staging systems: Hong Kong liver cancerWorld journal of hepatology · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Background Liver cancer is the sixth most common cancer worldwide and the second leading cause of cancer mortality. Chronic liver disease caused by viral infection, alcohol abuse, or other factors can lead to cirrhosis. Cirrhosis is the most important clinical risk factor for hepatocellular carcinoma (HCC) whereby the normal hepatic architecture is replaced by fibrous septa and a spectrum of nodules ranging from benign regenerative nodules to HCC, each one of them with different imaging features. Conclusions Furthermore, advanced techniques including the quantification of hepatic and intralesional fat and iron, magnetic resonance elastography, radiomics, radiogenomics, and positron emission tomography (PET)-MRI are highly promising for the extraction of new imaging biomarkers that reflect the tumor microenvironment and, in the future, may add decision-making value in the management of patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.